Copyright
©The Author(s) 2025.
World J Gastroenterol. Jan 14, 2025; 31(2): 101292
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.101292
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.101292
Figure 3 Association of vedolizumab serum trough concentrations (µg/mL) with clinical remission.
A: Concentration at week 0 vs clinical remission at week 48; B: Concentration at week 48 vs clinical remission at week 48; C: Concentration at week 48 vs clinical remission at 2 years.
- Citation: Chaemsupaphan T, Pudipeddi A, Lin HY, Paramsothy S, Kariyawasam VC, Kermeen M, Leong RW. Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study. World J Gastroenterol 2025; 31(2): 101292
- URL: https://www.wjgnet.com/1007-9327/full/v31/i2/101292.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i2.101292